Eli Lilly and Co. (LLY) announced that Pronounce study did not achieve its primary superiority endpoint of improved progression-free survival without grade four adverse events or G4PFS. No significant difference was observed between the treatment arms for secondary endpoints of progression-free survival or PFS overall survival, overall response rate and disease control rate. Toxicity profiles observed in the trial were consistent with the known safety profiles of each therapy.
The company said that announced results from its Pronounce trial of Alimta (pemetrexed for injection) for treatment of nonsquamous non-small cell lung cancer or NSCLC that was presented today at the American Society of Clinical Oncology annual meeting in Chicago, Ill.
The Pronounce trial compared an Alimta (pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and bevacizumab triplet regimen.
Pronounce is a randomized, open-label Phase III superiority study of first-line chemotherapy pemetrexed plus carboplatin (PemC regimen) followed by maintenance pemetrexed, compared to paclitaxel plus carboplatin plus bevacizumab (PacCBev regimen) followed by maintenance bevacizumab in patients with advanced nonsquamous NSCLC conducted in the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.